文献速递头颈部肿瘤放疗

局部晚期鼻咽癌诱导化疗反应欠佳:再诱导化疗还是直接放疗?

Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?
PubMed 文献 · Radiother Oncol · 2021-08-26

该回顾性研究纳入419例初程诱导化疗后反应欠佳(稳定或进展)的局部晚期鼻咽癌患者,比较再诱导化疗后放疗与直接放疗的疗效。再诱导组87例,直接放疗组332例,采用倾向评分匹配调整混杂。结果显示再诱导治疗未改善放疗后肿瘤控制,反而降低无局部区域复发生存和无进展生存,并增加血液学毒性。

要点

  • 再诱导化疗未改善放疗后完全缓解率(55.2% vs 52.5%,P=0.757)。
  • 再诱导组3年无局部区域复发生存更差(75.7% vs 83.1%,P=0.005)。
  • 再诱导组3年无进展生存更差(62.4% vs 68.3%,P=0.037),且3-4级血液学毒性增加。

核心结论

  • 对初程诱导化疗反应欠佳的局部晚期鼻咽癌患者,再诱导化疗较直接放疗降低无局部区域复发生存和无进展生存,并增加毒性。

研究设计与样本

  • 回顾性研究纳入419例初程诱导化疗后按RECIST标准评估为稳定疾病或疾病进展的局部晚期鼻咽癌患者。
  • 再诱导组87例接受额外周期替代诱导方案后放疗,直接放疗组332例不接受额外化疗直接放疗,采用倾向评分匹配调整潜在混杂因素。

主要发现

  • 再诱导组接受第二诱导方案后39.1%患者达到部分缓解。
  • 再诱导组与直接放疗组放疗后完全缓解率分别为55.2%和52.5%,差异无统计学意义(P=0.757)。
  • 再诱导组3年无局部区域复发生存率为75.7%,直接放疗组为83.1%(P=0.005)。
  • 再诱导组3年无进展生存率为62.4%,直接放疗组为68.3%(P=0.037)。
  • 再诱导组观察到3-4级贫血、血小板减少和肝酶升高增加。

临床怎么用

  • 对初程诱导化疗后反应欠佳的局部晚期鼻咽癌患者,直接放疗可能优于再诱导化疗。
  • 再诱导化疗前应权衡其生存获益缺乏及血液学毒性增加的风险。

局限性

  • 本研究为回顾性设计,尽管采用倾向评分匹配,仍可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unsatisfactory tumor response to induction chemotherapy (IC) is an adverse prognostic factor of locoregionally advanced nasopharyngeal carcinoma (LANPC). A re-induction strategy which applies additional cycles of an alternative IC regimen prior to radiotherapy (RT) has been adopted. METHODS: A total of 419 LANPC patients who attained suboptimal response (stable disease or disease progression) according to the Response Evaluation in Solid Tumors (RECIST) guideline after initial IC were retrospectively included. They were divided into those who received additional cycles of re-induction regimen prior to RT (re-induction group, n = 87) and those who had no additional chemotherapy (direct to RT group, n = 332). Propensity score matching (PSM) was used to adjust for potential confounders. Tumor response and long-term survival were compared between two groups. RESULTS: After receiving a second IC regimen, 39.1% of the patients in re-induction group attained partial response; however, the tumor control of subsequent RT was not significantly improved when compared with direct to RT group (patients attaining complete response after RT 55.2% vs. 52.5%, P = 0.757). Patients who received re-induction therapy showed worse locoregional relapse-free survival (LRFS) and progression-free survival (PFS) than those proceeded directly to RT (3-year LRFS 75.7% vs. 83.1%, P = 0.005; 3-year PFS 62.4% vs. 68.3%, P = 0.037). The increased hematological toxicities were observed in re-induction group that included grade 3-4 anemia, thrombocytopenia and liver enzyme increase. CONCLUSION: Re-induction therapy decreased LRFS and PFS and increased toxicities among patients who attain suboptimal response to initial IC regimen, as compared with direct to RT strategy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liu T, Liu LT, Lin JY, et al. Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy? Radiother Oncol. 2021. PMID: 34453953. doi:10.1016/j.radonc.2021.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。